Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

2014365 citationsJournal Articlehybrid Open Access

Authors

Sigrun Halvorsen · Oslo University Hospital

Dan Atar · Oslo University Hospital

H. Yang · Clinical Research Institute

R De Caterina · Fondazione Toscana Gabriele Monasterio

Çetin Erol · Ankara University

David E. Garcı́a · University of Washington

C. B. Granger ·

Abstract

The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Acute Ischemic Stroke Management Cardiac Arrhythmias and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 35, Issue 28, pp. 1864-1872

DOI: 10.1093/eurheartj/ehu046

Field-Weighted Citation Impact: 22.10